health
Preprint finds belzutifan’s added DFS benefit may weaken
A medRxiv preprint analysing reconstructed data from ten phase 3 kidney-cancer trials finds that the added disease-free-survival benefit of belzutifan may weaken after 12 months. Estimates of the later benefit differ by assessment method.